Skip to Content
Merck
All Photos(2)

Key Documents

F6755

Sigma-Aldrich

Fibrinogen from rat plasma

60-80% protein (≥60% of protein is clottable)

Synonym(s):

Factor I

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
EC Number:
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.61

biological source

rat plasma

Quality Level

form

powder

quality

60-80% protein (≥60% of protein is clottable)

mol wt

α-chain 63.5 kDa
β-chain 56 kDa
γ chain 47 kDa (about 4% carbohydrate content)
soluble dimer 340 kDa

concentration

60-80% (biuret)

technique(s)

cell culture | mammalian: suitable
immunoblotting: suitable

UniProt accession no.

storage temp.

−20°C

Gene Information

Application

Fibrinogen from rat plasma has been used:
  • in the preparation of growth factor solutions
  • to apply on discontinuous SDS-polyacrylamide gels for the detection of IgG (immunoglobulins) type antibodies by immunoblot analysis
  • to mix with cell suspension to form a clot and retain the cells for avoiding its dispersion during transplantation

Fibrinogen has been used in studies of haemostatic therapy in surgical and massive trauma patients. These studies have shown that fibrinogen may prove to be more superior in stopping blood loss when compared to using fresh frozen plasma (FFP).

Biochem/physiol Actions

Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.

Quality

Contains ~12% sodium citrate and ~18% sodium chloride.

Analysis Note

Protein determined by biuret.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Cell Transplantation as a Method to Investigate Spinal Cord Regeneration in Regenerative and Nonregenerative Xenopus Stages
Mendez-Olivos EE and LarraIn J
Cold Spring Harbor Protocols (2018)
Optimization of trophic support for neural stem cell grafts in sites of spinal cord injury
Robinson J and Lu P
Experimental Neurology, 291, 87-97 (2017)
Salmon fibrin glue in rats: antibody studies
Laidmae I, et al.
Biologicals : Journal of the International Association of Biological Standardization, 40(1), 55-60 (2012)
C Fenger-Eriksen et al.
British journal of anaesthesia, 101(6), 769-773 (2008-09-27)
Patients experiencing massive haemorrhage are at high risk of developing coagulopathy through loss, consumption, and dilution of coagulation factors and platelets. It has been reported that plasma fibrinogen concentrations may reach a critical low level relatively early during bleeding, calling
Richard J Fish et al.
Blood, 123(14), 2278-2281 (2014-02-21)
Mutations in the human fibrinogen genes can lead to the absence of circulating fibrinogen and cause congenital afibrinogenemia. This rare bleeding disorder is associated with a variable phenotype, which may be influenced by environment and genotype. Here, we present a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service